Intra-Cellular Therapies (NASDAQ:ITCI) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $132.00 target price on the biopharmaceutical company's stock.

Several other equities research analysts also recently commented on ITCI. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday, March 28th. They set a "hold" rating on the stock. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $106.23.

Remove Ads

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock remained flat at $131.87 during mid-day trading on Wednesday. Intra-Cellular Therapies has a 1 year low of $64.09 and a 1 year high of $131.98. The business's 50 day moving average is $129.62 and its 200-day moving average is $101.43. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Sell-side analysts anticipate that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Accredited Wealth Management LLC bought a new position in shares of Intra-Cellular Therapies in the fourth quarter worth approximately $28,000. MassMutual Private Wealth & Trust FSB boosted its holdings in Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 133 shares during the period. GAMMA Investing LLC boosted its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 240 shares during the period. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth $96,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies during the third quarter valued at about $97,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.